Cancer-targeted polymeric drugs

Current Cancer Drug Targets

Volumn 2, Issue 3, 2002, Pages 209-226

  Luo, Y ^a   Prestwich, G D ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; ALBUMIN; ANTIBODY; ANTINEOPLASTIC AGENT; ARGININE DEIMINASE; ASPARAGINASE; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DAUNORUBICIN; DNA; DOXORUBICIN; IODINATED POPPYSEED OIL; LYMPHOKINE; MACROGOL; MELPHALAN; METHOTREXATE; PACLITAXEL; POLYAMINOACID; POLYASPARTIC ACID; POLYMER; POLYSACCHARIDE; PRODRUG; PROTHECAN; RECOMBINANT INTERLEUKIN 2; STYRENE MALEIC ANHYDRIDE COPOLYMER; T 0128; TALAPORFIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE OXIDASE; ZINOSTATIN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG PENETRATION; DRUG RETENTION; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG TARGETING; ENDOCYTOSIS; HUMAN; MACROMOLECULE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; REVIEW; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; POLYMERS;

EID: 0036342837     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009023333836     Document Type: Review

References (143)

1. A covalent linkage between daunorubicin proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: In Vitro and In Vivo studies
2. Drug delivery and targeting
3. Liposomes as carriers of cancer chemotherapy
4. Albumin microspheres and microcapsules: Methodology of manufacturing techniques
5. Nanoparticle-based drug delivery systems
6. Structure and properties of pharmacologically active polymers
7. Dispersion of a polymeric prodrug of mitomycin C, mitomycin-dextran conjugate, in the perfused rat liver
8. Polymers for delivering peptides and proteins
9. Conjugation of camptothecins to poly-(L-glutamic acid)
10. Drug delivery systems: Water soluble taxol 2′-poly(ethylene glycol) ester prodrugs - Design and in vivo effectiveness
11. The tumor blood vessel as an ideal target for macromolecular anticancer agents
12. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line
13. Synthesis of antitumor-active conjugates of adriamycin or daunomycin with the copolymer of divinyl ether and maleic anhydride
14. Efficient delivery of platinum-containing compounds to malignant tumors
15. Tumor vascular permeability and the EPR effect in macromolecular therapeutics. A review
16. L-asparaginase and PEG asparaginase-past, present and future
17. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents-drug-polymer conjugates
18. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer carrier
19. Polymer conjugates with anticancer activity
20. Targeting of drugs to cell surface receptors
21. HPMA copolymer-anticancer drug conjugates design, activity, and mechanism of action
22. Polymer-drug conjugates: PDEPT and PELT: Basic principles for design and transfer from the laboratory to clinic
23. Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells
24. Passive tumor targeting of soluble macromolecules and drug conjugates
25. Macromolecular prodrugs: Blood interactions and targeting
26. Enzymatic degradation of poly(ethylene glycol) modified-dextrans
27. Solution properties of drug carriers based on [poly(N-2-hydroxypropyl)methacrylamide] containing biodegradable bonds
28. Antibody directed affinity therapy applied to the immune system: In Vivo effectiveness and limited toxicity of daunomycin conjugates to HPMA copolymers and targeting antibody
29. Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: In Vitro and In Vivo evaluation against murine melanoma
30. Polymers containing enzymically degradable bonds, XII. Effect of spacer structure on the rate of release of daunomycin and adriamycin from poly[N-(2-hydroxypropyl)methacrylamide] copolymer drug carriers In Vitro and antitumor activity measured In Vivo
31. Acid-sensitive polyethylene glycol, conjugates of doxorubicin: Preparation, In Vitro efficacy and intracellular distribution
32. 5-(2-hydroxyethyl)-L-glutamine]
33. (6-Maleimidocaproyl)hydrazone of doxorubicin: A new derivative for the preparation of immunoconjugates of doxorubicin
34. Lectin-mediated drug targeting: Preparation, binding characteristics, and antiproliferative activity of wheat germ agglutinin conjugated doxorubicin on Caco-2 cells
35. Cleavage of disulfide bonds in endocytosed macromolecules. A processing not associated with lysosomes or endosomes
36. Chemotherapy through lysosome with a DNA-daunomycin complex
37. Lysosomotropic agents
38. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients
39. SMANCS polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy
40. Tumor-targeted chemotherapy with lipid contrast medium and macromolecular anticancer drug (SMANCS) for renal cell carcinoma
41. Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and x-rays image
42. Polymer conjugates. Pharmacokinetic considerations for design and development
43. Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue
44. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts
45. PEG-prodrugs: An overview
46. Highly selective targeting of ovarian cancer with the photosensitizer PEG-M-THPC in a rat model
47. Prodrugs: Do they have advantages in clinical practice?
48. Distribution and tissue uptake of polyethylene glycol with different molecular weights after intravenous administration to mice
49. Antitumor activity of paclitaxel-2′-glycinate conjugated to poly(ethylene glycol): A water-soluble prodrug
50. Camptothecin delivery systems: Enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker
51. Camptothecin delivery systems: The anti-tumor activity of a camptothecin 20-O-polyethylene glycol ester transport form
52. Biodistribution of micelle-forming polymer-drug conjugates
53. Strategy and requirements of selective anticancer drug delivery to solid tumors with polymeric micelle
54. In Vivo antitumor activity of polymeric micelle anticancer drug against murein C 26 tumor
55. Development of the polymer micelle system for doxorubicin
56. Effect of the chemical structure of N-(2-hydroxylpropyl)methacrylamide copolymers on their stability to induce antibody formation in inbred strains of mice
57. Pharmacokinetics of high molecular weight agents
58. Polymer-bound derivatives of sarcolysin and their antitumor activity against mouse and human leukemia In Vitro
59. Macromolecular prodrugs for use in targeted cancer chemotherapy: Melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers
60. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers
61. Soluble synthetic polymers for targeting and controlled release of anticancer agents, particularly anthracycline antibiotics
62. Tumor tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma
63. Preclinical evaluation of polymer-bound doxorubicin
64. HPMA copolymer platinates as novel antitumour agents: In Vitro properties, pharmacokinetics, and antitumour activity In Vivo
65. Polymer-bound camptothecin: Initial biodistribution and antitumor activity studies
66. Phase I pharmacological study of water soluble polymer-conjugated paclitaxel (PNU 166945) administrated as a 1-hour infusion in patients with advanced solid tumors
67. Phase I clinical and pharmacokinetic study of PNU 166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel
68. Population pharmacokinetics in phase I drug development: A phase I study of PK1 in patients with solid tumors
69. Polymer conjugates for tumor targeting and intracytoplasmic delivery. The EPR effect as a common gateway?
70. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate
71. Long-circulating HPMA copolymer-adriamycin conjugates
72. A polymeric drug delivery system for the simultaneoous delivery of drugs activable by enzymes and/or light
73. Synthesis and photoproperties of a substituted zinc(11) phthalocyanine-N-(2-hydroxypropyl)methacrylamide copolymer conjugate
74. Synthesis of chelation products between chitosan and tetrachloroplinate toward the synthesis of water soluble cancer drugs
75. Distribution characteristics of carboxymethyl pullulan-peptide-doxorubicin conjugates in tumor-bearing rats: Different sequence of peptide spacers and doxorubicin contents
76. Functional polymers in drug delivery: Carrier-supported CDDP (cis-platin) complexes of polycarboxylates - Effect on human ovarian carcinoma
77. Complete regression of xenografted human carcinomas by camptothecin analogue-carboxymethyl dextran conjugate (T-0128)
78. Hydrophilic polymers for drug delivery
79. Polymeric prodrugs of mitomycin C designed for tumor tropism and sustained activation
80. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate
81. Sensitization of macromolecular chemotherapy: Modulation of EPR effect by radiation
82. Design of poly(A-malic acid)-5FU conjugate exhibiting antitumor activity
83. In Vitro and In Vivo antitumor activities of nanoparticles based on doxorubicin-PLGA conjugates
84. Immunoconjugates: Applications in targeted drug delivery for cancer therapy
85. Generation of cytotoxic agents by targeted enzymes
86. PDEPT: Polymer-directed enzyme prodrug therapy
87. Toxin-labeled monoclonal antibodies
88. Targeted cytokines for cancer immunotherapy
89. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates
90. Targeted chemotherapy in mice with peritoneally disseminated gastric cancer using monoclonal antibody-drug conjugate
91. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model
92. Effective cancer targeting using an anti-tumor tissue vascular endothelium-specific monoclonal antibody (TES-23)
93. Biodistribution of charged 17.1 Å photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer
94. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model
95. Targetable photoactivatable drugs. 3. In Vitro efficacy of polymer bound chlorin E6 toward human hepatocarcinoma cell line (PLC/PRF/5) targeted with galactosamine and to mouse splenocytes targeted with anti-thy 1.2 antibodies
96. N-(2-hydroxypropyl)methacrylamide copolymers targeted to the hepatocyte galactose-receptor: Pharmacokinetics in DBA2 mice
97. Preclinical evaluation of the cardiotoxicity of PK2: A novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumor agent
98. Biorecognition and biological activity of synthetic polymer glycoconjugates containing 5-fluorouracil
99. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates
100. Specificity of antibody-targeted drugs
101. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells In Vitro
102. Polymerizable Fab′ antibody fragments for targeting of anticancer drugs
103. Targeting of HPMA copolymer-drug conjugates to A2780/AD ovarian cancer cells using anti-P-glycoprotein antibodies or fragments
104. Polymeric drugs based on conjugates of synthetic and natural macromolecules I. Synthesis and physico-chemical characterization
105. Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab′)2-targeted conjugates and combined therapy with immunomodulators
106. Soluble polymers for lectin-mediated drug targeting
107. Antiproliferative effect of a lectin- and anti-thy-1.2 antibody-targeted HPMA copolymer-bound doxorubicin on primary and metastatic human colorectal carcinoma and on human colorectal carcinoma transfected with the mouse thy-1.2 gene
108. Folic acid targeting of protein conjugates into ascites tumor cells from ovarian cancer patients
109. Targeting of macromolecular prodrug to T-lymphocytes
110. In Vivo toxicity, pharmacokinetics, and anticancer activity of genistein linked to recombinant human epidermal growth factor
111. Targeting phthalocyanines to tumor cells using epidermal growth factor conjugates
112. A toxin conjugate containing transforming growth factor-alpha ricin A specifically inhibits growth of A431 human epidermoid cancer cells
113. Antitumor activity of basic fibroblast growth factor-saporin mitotoxin In Vitro and In Vivo
114. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation In Vitro and angiogenesis In Vivo
115. Synthesis of transferrin-mitomycin C conjugate as a receptor-mediated drug targeting system
116. In Vivo cytotoxicity and antineoplastic activity of a transferrin-daunorubicin conjugate
117. In Vitro cytotoxicity of paclitaxel-transferrin conjugate on H69 cells
118. Scavenger-receptor targeted photodynamic therapy
119. In Vitro activity of human chorionic gonadotropin (hCG) - Doxorubicin conjugates against ovarian cancer cells
120. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis
121. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate
122. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells
123. A lysosomal release type of macromolecular prodrug of doxorubicin using N-acetylpolygalactosamine as a targeting carrier to hepatoma
124. Targeted photodestruction of human colon cancer cells using charged 17.1A chlorine6 immunoconjugates
125. Experimental photodynamic treatment of ovarian carcinoma cells with immunoconjugates
126. Conjugation of 5-fluoro-2′-deoxyuridine with lactosaminated poly-L-lysine to reduce extrahepatic toxicity in the treatment of hepatocarcinomas
127. Design of poly(a-malic acid)-antitumor drug-saccharide conjugate exhibiting cell-specific antitumor activity
128. Biologically active polymer - Targeting polymeric antitumor agents
129. Synthesis of polyphosphazene/(diamine)-platinum(II)/carbohydrate conjugates
130. Photosensitizer targeting in photodynamic therapy. II. Conjugates of hematoporphyrin with serum lipoproteins
131. Targeting of tumor cells via the LDL receptor. Concept and synthesis of supramolecular biovectors which mimic LDL
132. PK1-PK2 (HPMA-doxorubicin conjugates): Potential for improved chemotherapy. Formulation challenges